The stock has a 36-month beta value of 1.33. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CTKB is 119.40M, and at present, short sellers hold a 3.75% of that float. On November 06, 2024, the average trading volume of CTKB was 610.50K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CTKB) stock’s latest price update
Cytek BioSciences Inc (NASDAQ: CTKB) has experienced a rise in its stock price by 29.04 compared to its previous closing price of 5.44. However, the company has seen a gain of 43.27% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-05 that Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Paul Goodson – Investor Relations Wenbin Jiang – Chief Executive Officer William McCombe – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Brendan Smith – TD Cowen Mason Carrico – Stephens John Barnidge – Piper Sandler Andrew Cooper – Raymond James Operator Thank you for standing by. At this time, I’d like to welcome everyone to the Cytek Biosciences’ Third Quarter 2024 Earnings Conference Call.
CTKB’s Market Performance
Cytek BioSciences Inc (CTKB) has experienced a 43.27% rise in stock performance for the past week, with a 39.29% rise in the past month, and a 29.52% rise in the past quarter. The volatility ratio for the week is 5.45%, and the volatility levels for the past 30 days are at 4.58% for CTKB. The simple moving average for the last 20 days is 36.20% for CTKB’s stock, with a simple moving average of 13.48% for the last 200 days.
Analysts’ Opinion of CTKB
Many brokerage firms have already submitted their reports for CTKB stocks, with Stephens repeating the rating for CTKB by listing it as a “Overweight.” The predicted price for CTKB in the upcoming period, according to Stephens is $9 based on the research report published on December 14, 2023 of the previous year 2023.
Piper Sandler gave a rating of “Overweight” to CTKB, setting the target price at $20 in the report published on January 06th of the previous year.
CTKB Trading at 34.39% from the 50-Day Moving Average
After a stumble in the market that brought CTKB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.88% of loss for the given period.
Volatility was left at 4.58%, however, over the last 30 days, the volatility rate increased by 5.45%, as shares surge +38.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.24% upper at present.
During the last 5 trading sessions, CTKB rose by +42.24%, which changed the moving average for the period of 200-days by -20.43% in comparison to the 20-day moving average, which settled at $5.15. In addition, Cytek BioSciences Inc saw -23.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTKB starting from Yan Ming, who sale 20,000 shares at the price of $5.87 back on Apr 19 ’24. After this action, Yan Ming now owns 5,988,502 shares of Cytek BioSciences Inc, valued at $117,400 using the latest closing price.
Yan Ming, the CHIEF TECHNOLOGY OFFICER of Cytek BioSciences Inc, sale 1,900 shares at $7.00 during a trade that took place back on Apr 09 ’24, which means that Yan Ming is holding 6,008,502 shares at $13,304 based on the most recent closing price.
Stock Fundamentals for CTKB
Current profitability levels for the company are sitting at:
- -0.12 for the present operating margin
- 0.55 for the gross margin
The net margin for Cytek BioSciences Inc stands at -0.05. The total capital return value is set at -0.06. Equity return is now at value -2.54, with -2.01 for asset returns.
Based on Cytek BioSciences Inc (CTKB), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 1.72. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -27.82.
Currently, EBITDA for the company is -17.11 million with net debt to EBITDA at 9.41. When we switch over and look at the enterprise to sales, we see a ratio of 3.9. The receivables turnover for the company is 3.82for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.21.
Conclusion
To sum up, Cytek BioSciences Inc (CTKB) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
